ArticleProceedings (Baylor University. Medical Center)2025
Artificial intelligence in melanoma diagnosis: ethical considerations and clinical implementation.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of artificial intelligence (AI) in dermatology, particularly for the diagnosis of melanoma, has demonstrated potential in improving early detection of cancer. Current AI-based systems, such as DermaSensor and Nevisense, have shown high sensitivity. In addition, open-source models like All Data Are Ext (ADAE) continue to show promise. Ethical, practical, and privacy concerns remain despite these advancements. Key challenges with these models include maintaining transparency with patients, ensuring privacy of patient data, and addressing discrepancies between AI and clinical determinations. Additional research, regulatory guidance, and open conversations are necessary to realize AI's full potential in the field of dermatology while preserving patient trust.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.